Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Background: We evaluated the effects of low doses of the tyrosine kinase Abelson (Abl) inhibitor Nilotinib, on safety and pharmacokinetics in Parkinson’s disease dementia or dementia with Lewy bodies. Objectives: The primary outcomes of this study were safety and tolerability; pharmacokinetics and target engagement were secondary, while clinical outcomes were exploratory. Methods: Twelve subjects were randomized into 150 mg ( n = 5) or 300 mg ( n = 7) groups and received Nilotinib orally every day for 24 weeks. Results: This study shows that 150 mg and 300 mg doses of Nilotinib appear to be safe and tolerated in subjects with advanced Parkinson’s disease. Nilotinib is detectable in the cerebrospinal fluid (CSF) and seems to engage the target Abl. Motor and cognitive outcomes suggest a possible beneficial effect on clinical outcomes. The CSF levels of homovanillic acid are significantly increased between baseline and 24 weeks of treatment. Exploratory CSF biomarkers were measured. Conclusions: This small proof-of-concept study lacks a placebo group and participants were not homogenous, resulting in baseline differences between and within groups. This limits the interpretations of the biomarker and clinical data, and any conclusions should be drawn cautiously. Nonetheless, the collective observations suggest that it is warranted to evaluate the safety and efficacy of Nilotinib in larger randomized, double-blind, placebo-controlled trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Nilotinib, proven to improve mitochondrial function,517 and clinical trials have been initiated to explore its application in PD.518,519”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [519]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ubiquitination Increases Parkin Activity to Promote Autophagic α-Synuclein Clearance
Lonskaya, I., Desforges, N. M., Hebron, M. L., & Moussa, C. E.-H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083914 · Cited by 86
Self-citationRetractedRepertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, K., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,203
The role of autophagy in neurodegenerative disease
Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059
Extensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study
Nixon, R. A., Wegiel, J., Kumar, A., Yu, W. H., Peterhoff, C., Cataldo, A., & Cuervo, A. M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.113 · Cited by 1,588
α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300227200 · Cited by 1,429
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
Boland, B., Kumar, A., Lee, S., Platt, F. M., Wegiel, J., Yu, W. H., & Nixon, R. A. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0800-08.2008 · Cited by 1,119
Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy
Ravikumar, B. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.9.1107 · Cited by 1,111
DJ‐1 has a role in antioxidative stress to prevent cell death
Taira, T., Saito, Y., Niki, T., Iguchi‐Ariga, S. M. M., Takahashi, K., & Ariga, H. (2004) · EMBO reports · doi:10.1038/sj.embor.7400074 · Cited by 853
Mollenhauer, B., Locascio, J. J., Schulz-Schaeffer, W., Sixel-Döring, F., Trenkwalder, C., & Schlossmacher, M. G. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70014-x · Cited by 622
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615
Huntingtin Expression Stimulates Endosomal–Lysosomal Activity, Endosome Tubulation, and Autophagy
Kegel, K. B., Kim, M., Sapp, E., McIntyre, C., Castaño, J. G., Aronin, N., & DiFiglia, M. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-19-07268.2000 · Cited by 533
Persson, L., Hårdemark, H. G., Gustafsson, J., Rundström, G., Mendel-Hartvig, I., Esscher, T., & Påhlman, S. (1987) · Stroke · doi:10.1161/01.str.18.5.911 · Cited by 486
(2001) · doi:10.1523/jneurosci.21-24-09549.2001 · Cited by 476
Mollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean, P. J., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.06.004 · Cited by 382 · cited 1×
“In PD, the CSF concentrations of -synuclein are reduced compared to healthy controls [32, 39–41] and the level of CSF -synuclein is even lower in patients with more advanced -synucleinopathies [40].”
BackgroundKang, J.-H. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3861 · Cited by 367
Hebron, M. L., Lonskaya, I., & Moussa, C. E. H. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt192 · Cited by 325
Self-citationKo, H. S., Lee, Y., Shin, J.-H., Karuppagounder, S. S., Gadad, B. S., Koleske, A. J., Pletnikova, O., Troncoso, J. C., Dawson, V. L., & Dawson, T. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006083107 · Cited by 283
Karuppagounder, S. S., Brahmachari, S., Lee, Y., Dawson, V. L., Dawson, T. M., & Ko, H. S. (2014) · Scientific Reports · doi:10.1038/srep04874 · Cited by 264
Jauch, E. C., Lindsell, C., Broderick, J., Fagan, S. C., Tilley, B. C., & Levine, S. R. (2006) · Stroke · doi:10.1161/01.str.0000242290.01174.9e · Cited by 251
Mahul-Mellier, A.-L., Fauvet, B., Gysbers, A., Dikiy, I., Oueslati, A., Georgeon, S., Lamontanara, A. J., Bisquertt, A., Eliezer, D., Masliah, E., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt674 · Cited by 219
Imam, S. Z., Zhou, Q., Yamamoto, A., Valente, A. J., Ali, S. F., Bains, M., Roberts, J. L., Kahle, P. J., Clark, R. A., & Li, S. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1833-10.2011 · Cited by 214 · cited 1×
“Abl activation induces misfolded protein pathology and oxidative stress in PD animal models and Abl inhibition with Nilotinib reduces oxidative stress [13, 21, 22, 24].”
BackgroundEvidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
Mahon, F.-X., Hayette, S., Lagarde, V., Belloc, F., Turcq, B., Nicolini, F., Belanger, C., Manley, P. W., Leroy, C., Etienne, G., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1008 · Cited by 212
Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?
Öhrfelt, A., Grognet, P., Andreasen, N., Wallin, A., Vanmechelen, E., Blennow, K., & Zetterberg, H. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2008.11.015 · Cited by 198
The Capable ABL: What Is Its Biological Function?
Wang, J. Y. J. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01454-13 · Cited by 193
Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies
Parnetti, L., Tiraboschi, P., Lanari, A., Peducci, M., Padiglioni, C., D'Amore, C., Pierguidi, L., Tambasco, N., Rossi, A., & Calabresi, P. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.02.016 · Cited by 173
DeRemer, D. L., Ustun, C., & Natarajan, K. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.014 · Cited by 172 · cited 1×
“All rights reserved This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC 4.0).”
MethodInfluentialCerebrospinal fluid Tau/α‐synuclein ratio in Parkinson's disease and degenerative dementias
Parnetti, L., Chiasserini, D., Bellomo, G., Giannandrea, D., De Carlo, C., Qureshi, M. M., Ardah, M. T., Varghese, S., Bonanni, L., Borroni, B., et al. (2011) · Movement Disorders · doi:10.1002/mds.23670 · Cited by 169
Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects
Mollenhauer, B., Trautmann, E., Taylor, P., Manninger, P., Sixel‐Döring, F., Ebentheuer, J., Trenkwalder, C., & Schlossmacher, M. G. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.11.004 · Cited by 163
Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases
Lleó, A., Cavedo, E., Parnetti, L., Vanderstichele, H., Herukka, S. K., Andreasen, N., Ghidoni, R., Lewczuk, P., Jeromin, A., Winblad, B., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.232 · Cited by 159
Goldstein, D. S., Holmes, C. S., & Sharabi, Y. (2012) · Brain · doi:10.1093/brain/aws055 · Cited by 154
Lonskaya, I., Hebron, M. L., Desforges, N. M., Schachter, J. B., & Moussa, C. E.-H. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1112-3 · Cited by 152
Self-citationKasuga, K., Tokutake, T., Ishikawa, A., Uchiyama, T., Tokuda, T., Onodera, O., Nishizawa, M., & Ikeuchi, T. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.197483 · Cited by 142
Lonskaya, I., Hebron, M. L., Desforges, N. M., Franjie, A., & Moussa, C. E. ‐. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302771 · Cited by 140
Self-citationHebron, M. L., Lonskaya, I., Sharpe, K., Weerasinghe, P. P. K., Algarzae, N. K., Shekoyan, A. R., & Moussa, C. E.-H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.419945 · Cited by 139
Self-citationOxidative insults induce DJ-1 upregulation and redistribution: Implications for neuroprotection
Lev, N., Ickowicz, D., Melamed, E., & Offen, D. (2008) · NeuroToxicology · doi:10.1016/j.neuro.2008.01.007 · Cited by 134
Tateno, F., Sakakibara, R., Kawai, T., Kishi, M., & Murano, T. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31823899cc · Cited by 121
Mollenhauer, B., Trautmann, E., Otte, B., Ng, J., Spreer, A., Lange, P., Sixel-Döring, F., Hakimi, M., VonSattel, J.-P., Nussbaum, R., et al. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0784-0 · Cited by 75
Mollenhauer, B., Bibl, M., Wiltfang, J., Steinacker, P., Ciesielczyk, B., Neubert, K., Trenkwalder, C., & Otto, M. (2006) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2006.035 · Cited by 75
Parkin degrades estrogen-related receptors to limit the expression of monoamine oxidases
Ren, Y., Jiang, H., Ma, D., Nakaso, K., & Feng, J. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq550 · Cited by 74
Zubenko, G. S., Marquis, J. K., Volicer, L., Direnfeld, L. K., Langlais, P. J., & Nixon, R. A. (1986) · Biological Psychiatry · doi:10.1016/0006-3223(86)90328-8 · Cited by 73
L. Hebron, M. (2014) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000259 · Cited by 68
Self-citationTargeted therapies and autophagy: new insights from chronic myeloid leukemia
Salomoni, P., & Calabretta, B. (2009) · Autophagy · doi:10.4161/auto.5.7.9509 · Cited by 52
Glial and Axonal Body Fluid Biomarkers Are Related to Infarct Volume, Severity, and Outcome
Petzold, A., Michel, P., Stock, M., & Schluep, M. (2008) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2008.02.002 · Cited by 50
Bioluminescent imaging of drug efflux at the blood–brain barrier mediated by the transporter ABCG2
Bakhsheshian, J., Wei, B.-R., Chang, K.-E., Shukla, S., Ambudkar, S. V., Simpson, R. M., Gottesman, M. M., & Hall, M. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312159110 · Cited by 48
Lonskaya, I., Hebron, M., Chen, W., Schachter, J., & Moussa, C. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-46 · Cited by 47
Self-citationPetzold, A., Groves, M., Leis, A. A., Scaravilli, F., & Stokic, D. S. (2010) · Muscle & Nerve · doi:10.1002/mus.21448 · Cited by 43
BCR-ABL1 Kinase: Hunting an Elusive Target with New Weapons
Skorski, T. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.11.001 · Cited by 18
Research works printed but not linked: 2
- 10.1007/s00109-013-1112-3 · DOI · Paper page
- Kang JH, 2013, JAMA Neurol, 70, 1277
Cited by
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing
Boland, B., Yu, W. H., Corti, O., Mollereau, B., Henriques, A., Bezard, E., Pastores, G. M., Rubinsztein, D. C., Nixon, R. A., Duchen, M. R., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.109 · Cited by 558
Progress towards therapies for disease modification in Parkinson's disease
Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R., & Foltynie, T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00061-2 · Cited by 419
Lang, A. E., & Espay, A. J. (2018) · Movement Disorders · doi:10.1002/mds.27360 · Cited by 370
Metadata
- Authors
- Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., Lawler, A., Rogers, S. L., Falconer, R. A., Ahn, J., Li, Z., & Moussa, C.
- Affiliations
- Department of Neurology, National Parkinson’s Foundation Center for Excellence, Translational Neurotherapeutics Program. Movement Disorders Program. MedStar Georgetown Hospital Washington, DC, USA
- Georgetown University Medical Center (US)
- MedStar Georgetown University Hospital (US)
- Corresponding author
- Moussa, Charbel
- Venue
- Journal of Parkinson’s Disease
- Publisher
- SAGE Publications
- Published
- 2016-06-03
- Volume
- 6
- Issue
- 3
- Pages
- 503-517
- ISSN
- 1877-7171 (ISSN-L)
- 1877-718X
- PMC
- PMC5008228
- OpenAlex
- W2462137239
- Cited by
- 265
- References
- 49
- Citations by year
- 2026: 14 · 2025: 12 · 2024: 20 · 2023: 23 · 2022: 37 · 2021: 34 · 2020: 32 · 2019: 38 · 2018: 30 · 2017: 17 · 2016: 7
- FWCI
- 23.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Parkinson s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Health and Human Services (UL1RR031975)
- Georgia Clinical and Translational Science Alliance
- National Institutes of Health (UL1TR001409, UL1TR000101)
- National Center for Research Resources (UL1RR031975)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- nilotinib, Parkinson's disease, dementia with Lewy bodies, ABL tyrosine kinase inhibitors, cerebrospinal fluid pharmacokinetics, target engagement, homovanillic acid, cerebrospinal fluid biomarkers, drug safety and tolerability
- MeSH terms
- Dementia, Follow-Up Studies, Humans, Parkinson Disease, Pyrimidines, Outcome Assessment, Health Care, Lewy Body Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.